- Home
- IONS vs IRT Comparison
IONS vs IRT Comparison
Compare IONS & IRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- IRT
- Stock Information
- Founded
- IONS 1989
- IRT 2009
- Country
- IONS United States
- IRT United States
- Employees
- IONS N/A
- IRT N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- IRT Real Estate Investment Trusts
- Sector
- IONS Health Care
- IRT Real Estate
- Exchange
- IONS Nasdaq
- IRT Nasdaq
- Market Cap
- IONS 4.6B
- IRT 4.8B
- IPO Year
- IONS 1991
- IRT 2013
- Fundamental
- Price
- IONS $32.26
- IRT $19.11
- Analyst Decision
- IONS Buy
- IRT Strong Buy
- Analyst Count
- IONS 18
- IRT 9
- Target Price
- IONS $57.41
- IRT $22.78
- AVG Volume (30 Days)
- IONS 1.7M
- IRT 1.7M
- Earning Date
- IONS 04-30-2025
- IRT 04-30-2025
- Dividend Yield
- IONS N/A
- IRT 3.35%
- EPS Growth
- IONS N/A
- IRT N/A
- EPS
- IONS N/A
- IRT 0.13
- Revenue
- IONS $717,253,000.00
- IRT $641,330,000.00
- Revenue This Year
- IONS N/A
- IRT $6.11
- Revenue Next Year
- IONS $27.39
- IRT $5.83
- P/E Ratio
- IONS N/A
- IRT $147.30
- Revenue Growth
- IONS N/A
- IRT N/A
- 52 Week Low
- IONS $23.95
- IRT $15.66
- 52 Week High
- IONS $52.34
- IRT $22.26
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- IRT 43.61
- Support Level
- IONS $31.66
- IRT $19.21
- Resistance Level
- IONS $33.98
- IRT $19.83
- Average True Range (ATR)
- IONS 1.30
- IRT 0.40
- MACD
- IONS 0.41
- IRT 0.04
- Stochastic Oscillator
- IONS 68.84
- IRT 31.56
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About IRT Independence Realty Trust Inc.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.